Literature DB >> 16710353

Developmental expression of ACE2 in the SHR kidney: a role in hypertension?

C Tikellis1, M E Cooper, K Bialkowski, C I Johnston, W C Burns, R A Lew, A I Smith, M C Thomas.   

Abstract

The abnormal development of the intrarenal renin-angiotensin system (RAS) is thought contribute to adult-onset hypertension in the spontaneously hypertensive rat (SHR). Angiotensin-converting enzyme 2 (ACE2) is a novel enzyme with complementary actions to that of ACE. Recent studies have shown that ACE2 expression is reduced in the adult SHR. However, its regulation in pre-hypertensive animals is unknown. In this study, we examine the developmental expression of ACE2 in the rodent kidney and its temporal expression, as it relates to the development of hypertension in the SHR model. Kidneys from SHR and normotensive Wistar Kyoto (WKY) rats (n=8-12/group) at birth, 6 weeks of age, and adulthood (80 days) were examined. Gene expression and activity of ACE2 were determined by real-time reverse transcription-polymerase chain reaction and quenched fluorescence assays, respectively. Renal expression was localized by in situ hybridization and immunohistochemistry. The expression and ACE2 activity are significantly increased in the SHR kidney at birth. With the onset of hypertension, the tubular expression of ACE2 falls in SHR compared to WKY and remains reduced in the adult SHR kidney. Glomerular expression is paradoxically increased in the SHR glomerulus. The overall developmental pattern of ACE2 expression in the SHR kidney is also modified, with declining expression over the course of renal development. The developmental pattern of ACE2 expression in the SHR kidney is altered before the onset of hypertension, consistent with the key role of the RAS in the pathogenesis of adult-onset hypertension. Further research is required to distinguish the contribution of these changes to the development and progression of hypertension in this model.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16710353     DOI: 10.1038/sj.ki.5000428

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  33 in total

Review 1.  Angiotensin-converting enzymes and drug discovery in cardiovascular diseases.

Authors:  Lijun Shi; Caiping Mao; Zhice Xu; Lubo Zhang
Journal:  Drug Discov Today       Date:  2010-02-17       Impact factor: 7.851

Review 2.  ACE and ACE2 in kidney disease.

Authors:  Sonoo Mizuiri; Yasushi Ohashi
Journal:  World J Nephrol       Date:  2015-02-06

3.  Reciprocal changes in renal ACE/ANG II and ACE2/ANG 1-7 are associated with enhanced collecting duct renin in Goldblatt hypertensive rats.

Authors:  Minolfa C Prieto; Romer A González-Villalobos; Fady T Botros; Victoria L Martin; Javier Pagán; Ryousuke Satou; Lucienne S Lara; Yumei Feng; Fernanda B Fernandes; Hiroyuki Kobori; Dulce E Casarini; L Gabriel Navar
Journal:  Am J Physiol Renal Physiol       Date:  2011-01-05

4.  Cardiovascular interactions between losartan and fructose in mice.

Authors:  Danielle Senador; Mary Key; K Bridget Brosnihan; Maria Claudia Irigoyen; Khalid M Elased; Mariana Morris
Journal:  J Cardiovasc Pharmacol Ther       Date:  2009-12-07       Impact factor: 2.457

Review 5.  ACE2 alterations in kidney disease.

Authors:  María José Soler; Jan Wysocki; Daniel Batlle
Journal:  Nephrol Dial Transplant       Date:  2013-08-16       Impact factor: 5.992

6.  Does ACE2 contribute to the development of hypertension?

Authors:  Mark C Chappell
Journal:  Hypertens Res       Date:  2009-12-18       Impact factor: 3.872

7.  Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension.

Authors:  Jan Wysocki; Minghao Ye; Eva Rodriguez; Francisco R González-Pacheco; Clara Barrios; Karla Evora; Manfred Schuster; Hans Loibner; K Bridget Brosnihan; Carlos M Ferrario; Josef M Penninger; Daniel Batlle
Journal:  Hypertension       Date:  2009-11-30       Impact factor: 10.190

Review 8.  Are we poised to target ACE2 for the next generation of antihypertensives?

Authors:  Anderson J Ferreira; Mohan K Raizada
Journal:  J Mol Med (Berl)       Date:  2008-05-01       Impact factor: 4.599

9.  Sex-Specific Changes in Renal Angiotensin-Converting Enzyme and Angiotensin-Converting Enzyme 2 Gene Expression and Enzyme Activity at Birth and Over the First Year of Life.

Authors:  Kai Chen; Jianli Bi; Yixin Su; Mark C Chappell; James C Rose
Journal:  Reprod Sci       Date:  2015-08-04       Impact factor: 3.060

Review 10.  Therapeutic implications of the vasoprotective axis of the renin-angiotensin system in cardiovascular diseases.

Authors:  Anderson J Ferreira; Robson A S Santos; Chastity N Bradford; Adam P Mecca; Colin Sumners; Michael J Katovich; Mohan K Raizada
Journal:  Hypertension       Date:  2009-12-28       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.